J&J Seeks Approval For Clinical Trials Of Its Single-Shot COVID-19 Vaccine On Adolescents Aged 12-17 Years In India

United States-based pharma giant Johnson and Johnson (J&J) has sought approval for clinical trial of its single-shot Covid-19 vaccine on adolescents aged 12-17 years in India.

The single-shot Covid vaccine developed by Johnson and Johnson has shown 85 per cent efficacy in preventing severe Covid-19 disease in phase 3 clinical trials.

"Johnson & Johnson is committed to facilitating global equitable access to its COVID-19 vaccine and recognize the unmet needs of children. On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12 – 17 years," Johnson & Johnson India spokesperson was quoted in a Economic Times report as saying.

Earlier this month, the single shot vaccine of J&J became the second COVID-19 vaccine which has been granted Emergency Use Authorisation (EUA) through the fast-track approval route by the Drug Controller General of India.

J&J has partnered with Indian vaccine maker Biological E Ltd for supply and manufacturing of its Covid-19 vaccine shot in the country.